Among all the approaches, only the inhibition of IL-17 activity allows for controlling both clinical manifestations (arthritis, enthesitis, spondylitis, and skin lesions) and spinal structural changes after a mere two years of treatment. The gene discussed is IL17A; the disease is spondylitis.